Metformin Plus Strength Training Shows Promise for Muscle Building in Seniors

The MASTERS trial explored whether metformin could amplify the muscle-building benefits of strength training in older adults. This innovative approach targeted age-related muscle loss, a critical factor in healthy longevity and functional independence.

The completed randomized controlled trial enrolled 109 senior participants over three years, from 2015 to 2018. Participants underwent progressive resistance training while receiving either metformin or placebo, allowing researchers to isolate the drug's potential enhancement effects on exercise adaptations.

The study measured changes in muscle mass and strength to determine if metformin could augment the well-established benefits of resistance training. Metformin's cellular mechanisms, including AMPK activation and improved insulin sensitivity, suggested potential for enhanced muscle protein synthesis and training adaptations.

While specific results weren't detailed in the available summary, this trial represents important research into pharmacological enhancement of exercise benefits. The combination approach could offer new strategies for combating sarcopenia, the age-related loss of muscle mass that affects mobility, metabolism, and overall health span.

For longevity optimization, this research highlights the potential for combining established interventions like resistance training with targeted medications. Understanding how metformin might enhance exercise adaptations could inform future protocols for maintaining muscle function throughout aging, ultimately supporting healthier, more independent later years.